Recent research has also shown that combining CPT-11 (the prodrug of SN-38) and PARPi achieved synergistic inhibition in both BRCA1 wild-type and BRCA1 mutant triple-negative breast cancer (TNBC) cell lines in vitro [127]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.